Drugs & Therapy Perspectives

, Volume 19, Issue 3, pp 22–25 | Cite as

Evidence points to influenza vaccination being cost-saving in healthy working adults

Pharmacoeconomics and Quality of Life


Influenza Acromegaly Influenza Vaccine Influenza Vaccination Ziprasidone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Postma MJ, Baltussen RMPM, Heijnen M-LA, et al. Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging 2000; 17: 217–27PubMedCrossRefGoogle Scholar
  2. 2.
    Postma ML, Jansema P, van Genugten MLL, et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002; 62 (7): 1013–24PubMedCrossRefGoogle Scholar
  3. 3.
    Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev 1196; 18: 64–76CrossRefGoogle Scholar
  4. 4.
    Smith JWG, Pollard R. Vaccination against influenza: a five-year study in the Post Office. J Hyg Camb 1979; 83: 157–80PubMedCrossRefGoogle Scholar
  5. 5.
    Yassi A, Kettner J, Hammond G, et al. Effectiveness and cost-benefit of an influenza vaccination program for health care workers. Can J Infect Dis 1991; 2: 101–8PubMedGoogle Scholar
  6. 6.
    Leighton L, Williams M, Aubery D, et al. Sickness absence following a campaign of vaccination against influenza in the workplace. Occup Med 1996; 46: 146–50CrossRefGoogle Scholar
  7. 7.
    Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997; 39: 408–14PubMedCrossRefGoogle Scholar
  8. 8.
    Kumpulainen V, Mäkelä M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997; 29: 181–5PubMedCrossRefGoogle Scholar
  9. 9.
    Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889–93PubMedCrossRefGoogle Scholar
  10. 10.
    Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284: 1655–63PubMedCrossRefGoogle Scholar
  11. 11.
    Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA 1983; 249: 3189–95PubMedCrossRefGoogle Scholar
  12. 12.
    Levy F. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996; 9 (S3): 62–6PubMedCrossRefGoogle Scholar
  13. 13.
    Burckel E, Ashraf T, De Sousa Filho JPG, et al. Economic impact of providing workplace influenza vaccination. Pharmacoeconomics 1999; 16 (5): 563–76PubMedCrossRefGoogle Scholar
  14. 14.
    Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161: 749–59PubMedCrossRefGoogle Scholar
  15. 15.
    Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281:908–13PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information 2003

Personalised recommendations